And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer
Lilly will be offering its Verzenio – the third CDK4/6 inhibitor to reach the US market – at a comparable list price to Pfizer's Ibrance and Novartis' Kisqali. FDA granted the drug a swift approval, just two months after it was accepted for priority review.
You may also be interested in...
Lilly reported strong sales growth for many of its recently launched products, but news of the potentially differentiating REWIND cardiovascular outcomes trial data dominated the pharma’s third quarter earnings call.
Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.
Merger appetites and competitive dynamics will continue to be assessed as investors grill the next round of biopharma companies presenting first quarter sales and earnings. Gilead and Pfizer will be particularly pressed on deals.